Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Jordan Healthcare Press.
Press releases published on August 14, 2025
Evoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 14, 2025
SOLANA BEACH, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI® (metoclopramide) nasal spray, today reported …
Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 14, 2025
PITTSBURGH, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory …
Microbix Reports Results for Q3 Fiscal 2025
GlobeNewswire
·
August 14, 2025
MISSISSAUGA, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and nine months of fiscal 2025 ended June 30, …
Larimar Therapeutics Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 14, 2025
Initial data from the 50 mg dose in the open label study and the adolescent PK run-in study planned for program update in September 2025 Adolescent participants from the PK run-in study and patients with FA who have not participated in prior nomlabofusp …
Lungpacer Announces CMS NTAP Approval for AeroPace® System in FY2026 IPPS Final Rule
GlobeNewswire
·
August 14, 2025
Exton, Pa., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Lungpacer Medical Inc., a medical technology company focused on neurostimulation therapies for critically ill patients, today announced that the Centers for Medicare …
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
GlobeNewswire
·
August 14, 2025
Planned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinic Reported positive topline data from the core, blinded stage of the …
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 14, 2025
VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaborations Established with Essity and …
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 14, 2025
– WTX-124 Phase 1/1b clinical trial on track for interim data readout in the fourth quarter of 2025, including patients in both the monotherapy and combination expansion arms of cutaneous melanoma and renal cell carcinoma – – Planning to engage with U.S. …
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025
GlobeNewswire
·
August 14, 2025
BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented results from its Phase 1 …
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
GlobeNewswire
·
August 14, 2025
CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) …
Balt USA Responds to Patent Infringement Lawsuit Filed by Route 92 Medical
GlobeNewswire
·
August 14, 2025
IRVINE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Balt USA, LLC (“Balt”), a global leader in neurovascular medical devices, today announced it intends to vigorously defend against the allegations of patent infringement filed by Route 92 Medical, Inc. …
Tilray Brands Reconfirms Strategy to Regain Nasdaq Compliance; Requests Extension to Meet Listing Requirements
GlobeNewswire
·
August 14, 2025
NEW YORK and LEAMINGTON, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle consumer packaged goods company at the forefront of the cannabis, beverage, and wellness …
Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 14, 2025
PRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg); Company to provide an update with preliminary clinical data, including PK/PD, safety and initial clinical activity by year end 2025 Phase 1 study of …
Denovo Biopharma LLC to Participate in Upcoming Investor Events
GlobeNewswire
·
August 14, 2025
SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative drugs, today announced that company management will participate in upcoming August and September investor events. The …
SEED Therapeutics Named Finalist for 2025 Prix Galien USA “Best Start-Up” Award
GlobeNewswire
·
August 14, 2025
Nomination recognizes SEED’s pioneering work in molecular glue development in targeted protein degradation to address high unmet medical needs Follows recent FDA IND clearance for SEED’s lead asset RBM39 degrader ST-01156 KING OF PRUSSIA, Pa., Aug. 14, …
Traws Pharma Reports Second Quarter 2025 Results and Business Highlights
GlobeNewswire
·
August 14, 2025
Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratutrelvir, a ritonavir-free, protease inhibitor regimen in …
SRx Health Solutions Announces the Cancellation of Approximately 18.8 Million Shares of its Capital Stock
GlobeNewswire
·
August 14, 2025
TAMPA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”), a leading global health and wellness company, today announced that further to the previously disclosed grant of an Initial Order under the …
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
August 14, 2025
– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 – – On track to dose first participant in Phase 1 clinical trial for SL-325 in Q3 2025 – – Cash …
Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock
GlobeNewswire
·
August 14, 2025
WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and …
Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update
GlobeNewswire
·
August 14, 2025
~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in the Second Quarter of 2025, Including Notable Quarter-Over-Quarter Growth in Both Large Community Practices and Academic Centers, Supported by Targeted Sales …